ENTOS
LIVE

Serial Number

97590585

Owner

Entos Pharmaceuticals Inc.

Attorney

Theodore R. Remaklus

Filing Date

Sep 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ENTOS Trademark

Serial Number: 97590585

ENTOS is a trademark filed by Entos Pharmaceuticals Inc. on September 14, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

Entos Pharmaceuticals Inc.

10230 Jasper Avenue, Unit 4550
Edmonton, Alberta T5J4P6 , CA

Entity Type: 03

Trademark Details

Filing Date

September 14, 2022

Registration Date

Not Registered

Published for Opposition

September 10, 2024

Goods & Services

Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for laboratory use for use in the biotechnological industry; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use

Nucleic acid sequencers for scientific purposes

Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection

Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the name of pneumonia, kidneys in the name of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; cell culture media for cultivating human, animal, plant or microorganism cells for use in the biotechnological industry

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 19, 2026 EXRA
SOU EXTENSION 3 GRANTED
May 19, 2026 EX3G
SOU TEAS EXTENSION RECEIVED
Apr 20, 2026 EEXT
SOU EXTENSION 3 FILED
Apr 19, 2026 EXT3
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 17, 2025 EXRA
SOU EXTENSION 2 GRANTED
Nov 17, 2025 EX2G
SOU TEAS EXTENSION RECEIVED
Oct 30, 2025 EEXT
SOU EXTENSION 2 FILED
Oct 29, 2025 EXT2
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 5, 2025 EXRA
SOU EXTENSION 1 GRANTED
May 5, 2025 EX1G
SOU EXTENSION 1 FILED
May 1, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
May 1, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 5, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 10, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 10, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 21, 2024 NONP
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Aug 1, 2024 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 25, 2024 CNSA
DIVISIONAL PROCESSING COMPLETE
Jun 25, 2024 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 12, 2024 AITU
ASSIGNED TO LIE
Apr 6, 2024 ALIE
DIVISIONAL REQUEST RECEIVED
Nov 16, 2023 DRRR
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 16, 2023 TROA
TEAS REQUEST TO DIVIDE RECEIVED
Nov 16, 2023 ERTD
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 27, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 27, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 27, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 27, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 27, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 26, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 30, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2022 NWOS
NEW APPLICATION ENTERED
Sep 17, 2022 NWAP